language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
TFXTFX

$106.12

+3.07
arrow_drop_up2.98%
Current Market·update15 Jan 2026 19:09
Day's Range
102.73-106.53
52-week Range
102.58-185.94

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2025-11-06
Next Earnings TimeBefore Market Open
Volume339.3K
Average Volume 30d728.06K

AI TFX Summary

Powered by LiveAI
💰
35.98
Valuation (P/E Ratio)
Higher than industry average, suggesting growth expectations
📈
-0.15
EPS Growth (YoY)
Recent decline in earnings per share
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Hold
68

Teleflex exhibits solid fundamental strengths with consistent earnings and a manageable debt load. However, recent performance has been weak, and valuation metrics suggest it may be fairly valued or slightly overvalued. Technical indicators point to a neutral to slightly bearish short-term outlook. The company operates in a stable, but not high-growth, sector.

Neutral

Thematic

55

Teleflex operates in the medical devices sector, which benefits from an aging global population and increasing healthcare spending. However, it faces intense competition and potential regulatory headwinds. Its focus on critical care and surgical applications provides a stable demand base.

Strong

Fundamental

75

Teleflex demonstrates robust profitability and a solid balance sheet. Revenue growth has been stable, and earnings have consistently met or exceeded expectations. The company's net profit margin is healthy, supported by efficient operations.

Bearish

Technical

40

The stock is trading significantly below its 52-week high and has experienced a substantial decline over the past year. While there are some short-term indicators suggesting potential stabilization, the overall trend is bearish. Moving averages and momentum indicators signal caution.

FactorScore
Healthcare Spending Growth75
Medical Device Innovation60
Regulatory Environment40
Competitive Landscape50
Aging Population Tailwinds70
FactorScore
Valuation50
Profitability65
Growth30
Balance Sheet Health85
Cash Flow90
Earnings Consistency75
FactorScore
Trend Analysis30
Momentum40
Volume Confirmation50
Support & Resistance40
Short-Term Oscillators35

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (6)

Earnings Performance chevron_right

Consistent EPS Beat

The company has exceeded earnings per share (EPS) estimates for the last 8 consecutive quarters, demonstrating consistent operational execution and profitability.

Valuation chevron_right

Undervalued Relative to Peers

With a P/E ratio of 35.97, the stock appears relatively undervalued compared to its industry peers, suggesting potential for price appreciation.

Show More 🔒
thumb_down

Bearish Points (8)

Valuation Risk chevron_right

High P/E Ratio

The current P/E ratio of 35.97 is significantly higher than the historical average and industry benchmarks, potentially indicating overvaluation and a risk of price correction.

Growth Deceleration chevron_right

Slowing Revenue Growth

Revenue for the latest reported period (2024Q4) shows a decline of 17.2% year-over-year, indicating a significant slowdown in top-line growth.

Show More 🔒

Calendar

May 2025

20

Ex-Dividend Date

June 2025

16

Next Dividend Date

July 2025

31

Next Earnings Date

EPS Est.
Revenue Est.

H: $3.42

A: $3.37

L: $3.24

H: 775.00M

A: 771.53M

L: 759.30M

Profile

Employees (FY)14.1K
ISIN-
FIGI-

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, the measurement of blood pressure, and the collection of blood samples. The company also offers interventional products, including various coronary catheters, structural heart support devices, peripheral intervention products, and mechanical circulatory support platform; and Arrow branded intra-aortic balloon pumps and catheters, Guideliner, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway, pain management, and hemostatic products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligating clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology, as well as bladder management services; and OEM products, which includes the TFX Medical OEM, TFX OEM, Deknatel, and HPC Medical brands. It serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Seasonals

2025
2024
2023
2022
2021

Price Target

149.62 USD

The 39 analysts offering 1 year price forecasts for TFX have a max estimate of 200.00 and a min estimate of 123.00.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
44M (99.65%)
Closely held shares
155K (0.35%)
44.2M
Free Float shares
44M (99.65%)
Closely held shares
155K (0.35%)

Capital Structure

Market cap
5.13B
Debt
1.76B
Minority interest
0.00
Cash & equivalents
290.19M
Enterprise value
6.6B

Valuation - Summary

Market Cap
5.13B
Net income
69.4M(1.35%)
Revenue
2.26B(44.02%)
5.13B
Market Cap
5.13B
Net income
69.4M(1.35%)
Revenue
2.26B(44.02%)
Price to earning ratio (P/E)74.00x
Price to sales ratio (P/S)2.30x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
3.05B
COGS
1.34B
Gross Profit
1.7B
OpEx
1.16B
Operating Income
545.74M
Other & Taxes
476.06M
Net Income
69.67M

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒